T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase inhibitor (TKI), exhibiting potential of multiple anti-cancer indications. The Phase I trial is to evaluate safety and tolerability of T-1301, the recommended Phase 2 dose (RP2D), and the pharmacokinetics in human, and to assess the preliminary anti-tumor activities of T-1301.
News
News
![](https://www.taivex.com/wp-content/uploads/2022/10/iStock-news.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/橙圓元素.png)
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021
![](https://www.taivex.com/wp-content/uploads/2016/09/iStock-1431634510.jpg)
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-1.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-2-1.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-3.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-2.png)
![](https://www.taivex.com/wp-content/uploads/2022/10/pill-1-1.png)